MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat sarcoma)-mutant mCRC (Metastatic colorectal cancer) diagnosis who convert to RAS wild-type using monitoring of the RAS mutation status by liquid biopsy.
Epistemonikos ID: a93e39ec98bb7e20be6dbc00923a09657bc81aaf
First added on: May 07, 2024